Radiation oncology firm Accuray has garnered U.S. Food and Drug Administration (FDA) 510(k) clearance for its Radixact treatment delivery platform.
Radixact builds upon the TomoTherapy platform and includes Accuray's Precision treatment planning system and iDMS data management system, according to the vendor. Radixact features expanded delivery capabilities to enable treatment with image-guided intensity-modulated radiation therapy (IG-IMRT) for a wider range of patients, the company said. It also incorporates new database features designed to make the ring gantry-based system easier to operate and integrate within a radiation oncology department.
In addition, Radixact includes a new linear accelerator, megavoltage CT imaging, and helical treatment delivery, so clinicians can apply conformal and homogenous dose distributions to any target volume while sparing normal healthy tissue during each treatment fraction, according to the firm.
Accuray also noted that the Precision treatment planning system offers automated workflows and midcourse decision-making tools to enable clinicians to adapt delivery to changes in tumor size, shape, and location. The company plans to release Radixact late in its 2017 fiscal first quarter, which runs from July to September 2016.
